<SEC-DOCUMENT>0001193125-16-744603.txt : 20161024
<SEC-HEADER>0001193125-16-744603.hdr.sgml : 20161024
<ACCEPTANCE-DATETIME>20161024090032
ACCESSION NUMBER:		0001193125-16-744603
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20161024
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20161024
DATE AS OF CHANGE:		20161024

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330024450
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		161947334

	BUSINESS ADDRESS:	
		STREET 1:		10480 WATERIDGE CIRCLE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858 597-6006

	MAIL ADDRESS:	
		STREET 1:		10480 WATERIDGE CIRCLE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d276704d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C.&nbsp;20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section 13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported) October 24, 2016 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>INOVIO PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-14888 <U></U></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>33-0969592</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>660 W. Germantown Pike, Suite 110</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plymouth Meeting,&nbsp;Pennsylvania</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>19462</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code:&nbsp;<U>(267) 440-4200</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B></B><U>Item&nbsp;8.01</U>.<U></U></TD>
<TD ALIGN="left" VALIGN="top"><U>Other Events</U>.<B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October 24, 2016, we issued a press release to announce that
the U.S. Food and Drug Administration (FDA) has placed a clinical hold on our proposed phase III clinical program for VGX-3100.&nbsp;The press release is attached to this Form 8-K, and the text of the press release is incorporated by reference into
this Form 8-K as though fully set forth herein. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><U>Item&nbsp;9.01</U>.<U></U></TD>
<TD ALIGN="left" VALIGN="top"><U>Financial Statements and Exhibits</U>. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit&nbsp;No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release dated October 24, 2016</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">INOVIO PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Peter Kies</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Peter Kies,</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date:&nbsp;October 24, 2016 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d276704dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g276704g89h83.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>NEWS RELEASE</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immediate Release </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CONTACTS:</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investors:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, <U>bhertel@inovio.com</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Media:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, <U>jrichardson@inovio.com</U></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inovio Announces FDA Request for Additional Information </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For Phase III Program; Trial Initiation Delayed </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLYMOUTH MEETING, Pa. &#150; October&nbsp;24, 2016 &#150; Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that the U.S. Food and Drug
Administration (FDA) has placed a clinical hold on its proposed phase III clinical program for VGX-3100. A clinical hold is a notification issued by the FDA to a trial sponsor to delay a proposed clinical trial or suspend an ongoing clinical trial.
This study has not yet been initiated and has not enrolled or dosed subjects. Additionally, the hold does not pertain to any of Inovio&#146;s other ongoing clinical studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio anticipates receiving a formal letter with complete information from the FDA within 30 days. In its initial communication, the FDA has requested
additional data to support the shelf-life of the newly designed and manufactured disposable parts of the CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> 5PSP immunotherapy delivery device. Inovio is working diligently with the
FDA to address its concerns and anticipates that the requested data will be available before the end of this year. Inovio estimates that the start of the phase III clinical program will be delayed until the first half of 2017 pending resolution of
the FDA&#146;s requests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Inovio Pharmaceuticals, Inc</B>. <B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported
generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a
growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial
Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University. For more information, visit <U>www.inovio.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">#&nbsp;#&nbsp;#&nbsp;# </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release
contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs. Actual
events or results may differ from the expectations </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs, including our ability to obtain a
release of the clinical hold from the FDA, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our
ability to support our broad pipeline of SynCon<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> active immunotherapy and vaccine products, the ability of our collaborators to attain development and commercial milestones for products we
license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the
company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop, issues involving product liability, issues involving patents
and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others
or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company&#146;s
technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2015,
our Form 10-Q for the quarter ended&nbsp;June 30, 2016,&nbsp;and other regulatory filings from time to time. There can be no assurance that any product in Inovio&#146;s pipeline will be successfully developed or manufactured, that final results of
clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate. </I></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g276704g89h83.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g276704g89h83.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
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MU K\JOV//V;[[]KCX^:=X;,TT5K*S7VKW@.YXX%.9&S_ 'V)P">[9[5]@?\
M!=_5YAHWP[T\,P@DN+RX89.-RI&H./7#&F?\$)?"$']D_$/7<@WGG6M@#_=0
M*[G\R1^5**Y5<E,^Z/A;\*O#_P &/!5EX?\ #.F6VE:58H%CBB7!8]V8]68]
M2QY-=$ !2*-J@"EJ"CS3]I_]EWPQ^U-\.;K0O$-G'YH0FQOT0?:-/EQPZ-UQ
MG&5Z$5^,VO:7XF_9+^/D]J)6T_Q+X+U(%)8B5#LC AE]4=>QZAJ_>-P2IQUK
M\F_^"T_ARWTC]KFUO(559=5T.WEGP,9=7=,G\%%7'7W0/TU^ OQ9M?CG\'?#
MGBVS!C@UVQCN3'WB<C#I^#!A^%%?/_\ P1K\2SZ_^QG:VTN=FD:M=VL1)/*Y
M#X_ N:*E@<E_P7._Y-]\)_\ 8>_]H25Y/_P0F_Y*_P".O^P1!_Z.->L?\%SS
MC]GWPE_V'O\ VA)7D_\ P0F_Y*_XZ_[!$'_HXU2DN5H#]-:_+K_@N9_R<)X4
M_P"Q?/\ Z/>OU%K\NO\ @N9_R<+X4'_4OG_T>]%/X@/H?_@BE\W[(=UGMK]W
M_*.OKZOD#_@B?S^R%=_]A^[_ )1U]?U,MP.&_:=_Y-Q\>?\ 8 O?_1#U^-_[
M#?\ R=S\-/\ L.6_]:_9#]IW_DW'QY_V +W_ -$/7XW_ +#G'[77PT_[#EO_
M %JXR2BT!^X\B[HR#T(K^>/_ (*Y^'IM(_;Q\:3R*474)4G1B/O?*%/ZBOZ'
M7^Z:_*?_ (+G?L;W.O>(X/&.G6X9I5)#KP"W="?0_P \5]CP!G5/+,V52O\
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M\+T_:1_Z('X9_P#"\@_^,T?\+T_:1_Z('X9_\+R#_P",U:RG$+[5/_P;3_\
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MO[?R-?UK.J:J&&'CED VQ'_<3:N/7->^9'J*^</^%Z_M(_\ 1 _#/_A>0?\
MQFC_ (7I^TC_ -$#\,_^%Y!_\9IO*<0_M4__  ;3_P#D@_MFA_+4_P#!53_Y
M ^C\CU%5M6MS?:?<0*P4S1,@)Y R"*^>?^%Z?M(_]$#\,_\ A>0?_&:/^%Z?
MM(_]$#\,_P#A>0?_ !FE_9&(_FI_^#:?_P D']LT/Y:G_@JI_P#('S5I'_!#
MWQ9IGBZUU(^//#KI;WJ71C%C,"P60/C.>N!BOTAB.!R?\*^<_P#A>G[2/_1
M_#/_ (7D'_QFC_A>G[2/_1 _#/\ X7D'_P 9IO*<0_M4_P#P;3_^2#^V:'\M
M3_P54_\ D#Z.)!'6N'^/?[/'A']I/P5)H/BW28=1M#EH91\EQ:/_ 'XI!RK?
M3@]\UY3_ ,+T_:1_Z('X9_\ "\@_^,T?\+T_:1_Z('X9_P#"\@_^,TEE&(_F
MI_\ @VG_ /)!_;-#^6I_X*J?_('RU\8?^"'/B;2+V:X\#>)],UBSR3%::HIM
MKE!G[OF+E&QZD#->:0_\$??CF]P8SHN@Q+T\QM7BP??CG]*^\/\ A>G[2/\
MT0/PS_X7D'_QFC_A>G[2/_1 _#/_ (7D'_QFK_LO$_S4_P#P;3_^2$\XP_\
M+4_\%5/_ ) ^>O@5_P $/98M1M[WXC>)XY;="&?3='#*9.AVO.W0=OE7GUK[
MV^'/P[T+X3^$K70O#NEVFCZ38KMAMK=-JCU)[DGN3DGUKP[_ (7I^TC_ -$#
M\,_^%Y!_\9H/QU_:2[? 3PSG_L?(/_C-2\JQ#WE3_P#!M/\ ^2'_ &S0_EJ?
M^"JG_P @?1P(/0BBO&?@O\4/C-XL\=)9^-?A7HOA+0S"[MJ%MXICU!UD'W4\
MI8U)!]<\45P8FA*A/DDT_249+[TVCMPV)C6ASQ37K&2?W-)G-_\ !07X]ZO\
M#+'X;C2_$<_A6U\4>+DT;4]0MM(_M6XBMS9W4V(X=CDL9(HQD*<#-=?^Q7X_
M\9_$GX-2ZAXWMKA+Z/5KVVTZ[N=..FW&K:>DQ6VNY+4\PO(F"5..F<#.*Z?X
MJ?!"P^*_B;P1JEY>7=M-X&US^WK58,!;B7[-/;['R/N[9V/&.0*[0=:R.FQX
MG^VC^T%JG[/,'PWOM/%S)::[XTM-&U.&VL&O;BXM9(+AV2*-06+EHTY49 !K
MFO#G[8E_\1/VY/"G@C2;37M,\-7WA'5-7OH-8T&;3YIKF&YLXX6C:95)4++)
MD+QRN:]=^+WP1L/C'J?@ZYOKN[M6\&>((?$-JL&W$\T4<L81\@_(1*V<<\"H
MM=^ VG:]^T/X?^(\MY>IJGA[1+W0X;52OV>6*ZE@D=V&,[@;=0,'HQH [AL>
M63ST[=:^1_$W_!0N^T;]M:'01)X?3X3V>HQ^"=2OGNH_MT?B*=1+$RIG/V9#
MLMF./];,.PKZSU*VDO-.GABG>VEEC9$F0 M$Q& P!X)!YY]*\&LO^":7PHA^
M!,_@F?PWIMY<W-K+%-XBFLX6UJ2YD8R->_:=N\7'FMY@8'A@,< "@#WX?ZL'
MOBOC']N7]L?Q-\&?VI[;P9I7C5O#3:CX-;4_#^FP^'1JTOB#63<O'%9G"EE#
MJH& RGDG/%?8/AK2)]#\,V%A<WUQJ=Q9VT<$MY. );IE4*9' P-S$9..,FO*
MOC7^Q+X4^/?Q U7Q!K\^I/-JGAV/P\(H)1%]C$=U]JBNH7'SI/'+AE8'C% '
MIG@#4]3UCP'HMYKMC%IFM75C!+J%HC[TM;AHU,D8;N%<D9]J\#_X*"_MBZ]^
MRAK/PV&@Z7#K%OJNJW%[XEAQF:WT*T@,E[<1CJ6CWQOCN%8=Z^@/!^AW7AWP
MMIVGWVIW&M7=G;)#-?W"*DMXR@ R.J *&;&3@ 9-<QXC^ >C^+/C39>-M2:2
M]N=.T*ZT""RE16MEBN9(WG<@C)9A$B'MMR,<T >)?$#]O2>W_;N^''@/P\D5
M_P"!-0#6GB36D4/#%J-[9O<Z7:HW]YXX9)#CM)'G[PKZG!&<#%?/O@S_ ()N
M^ _AI\$M)\#^')]8TNST;Q7!XOAO3.)[Q[N&X$J*[N#NC$86 #M$H Z9KW]4
M"$XXRW- 'RG^W/\ MXZI\ /BQHVB^%I=$NX?"-LOBGQ[!=SHDT>C,_DK% &(
M/VALRS@#^"T8?QBOJ/P_K5KXDT>WU"QN8;RRO8DGMYXF#)-&RAE=2.H(((^M
M>4^'_P!ACX>P^(/%>M>)= TCQQKOC#5)-1OM0UW3;>ZF5"BQQ6T99/DABB54
M51[DY))KK/V>/@A:?LY?"C3O!NFZCJ.HZ1HIDCT[[:P>6TMC(S16P8 92)2(
MU)YVJH).* .+_:;^,7BC0OB1X"^'7@J;3=-\1_$&6\D_M>_A\^'1[*SC62>1
M(<CSIVWHJ(2%&XL<A<'I_AC\/O&W@GQ+)+KOQ#F\8:/+;E?LUYH]M:W$$^00
MZR0!04*[@592>A!ZU+\=OV=M$^/UCI@U"XU+2M8\/77]H:+K.F3>1?Z1<%60
MO$^""&1F5D8%74D$&JWPD^"_B;P+KEQJ/B7XE>)/&\TD MX8+NTM;.T@7.2_
ME01KND. -Q/3. ,T =SXEO9=.\,:A<Q$+-;VLDJ$C.&521Q]17RO_P $V?V@
M/&'[1'P_\'^(_$WBOQAJ=]KF@)J-Y97/@Y--TD3.!GR;H1#> 3\H#G<*^K]5
MTY=6TFYM'9D2YA:$LO50RD9'YUXY^RS^R=K7[+_AW0_#T7Q*U_Q'X2\.:>NF
MZ?I-]IMG&(8U&$)ECC61BH]3SWS0![2!A1W-?*.E?M8>,[K_ ()A^./B?)>6
M1\7Z%!X@DM+C[(HA4V=]=0PDQ]#A(DSZ\U]7E?DQFOG36_\ @G;IVIZ5K/A:
MW\;^*].^%_B.]GO]3\'P"#[/.\\AEGB2X9#/'!)(69HU?'S, 0#B@#WCP9J4
MVM^#=)O+AE>XN[*&:1@N 69 20.W)KY]_;0\5?$+P1\8/A19>%OB!<^'M,^(
M'B=/#UW:?V-:70MXQ975P98WD4MO+0J.<C!/%?2-C9Q:?90V\$:10P(L<:*,
M*B@8  ] *XOXO? ;3?C'XJ\":M?7=Y;3^ -=&O6:P;=L\OV>:#9)D?=VS,>,
M'(% '7:/93Z?HMM!=73W]S#"J2W+(L;3L!@N57@$GG X&:\GM/C!K\_[>E]X
M!:>#_A&H/ 4&O)%Y(\T7;7\D#-OZ[?+4#;TSS7L3C*FN'@^!6GV_[1EQ\21>
M7G]JW/AV/PVUM\OD"!+E[@..,[]SD=<8[4 ;?Q+\=6OPO^&NO^)KR.6:T\/:
M;<:E,D2YDD2&)I&51ZD*0/>O$OA1HGQD^-/PST;QM=?$RS\+7WB2UAU6TT.Q
MT&VO--L()E62.!Y'_?3,$8!I%= 23M  %?0M]80ZKI\UK<Q1SV]S&8I8I%#)
M(C#!4@]002,5X7H/[$^I?#^SM]"\(?%7QQX7\"6SCR?#]NEK/]CBW9^SV]S+
M$TT,(Z!0QVKPI Q@ ]W@!\A-Y#/M&XXP">]?/7[?_P"U%K_P0\/Z#X=^'T_A
MY_B1XJFDN-.M]7N$BMA96B^==NY8@ LH6%/^FDZ>AKZ%6/;;A,DX7&6.2?K7
MEFL_L<^"O&GQFUOQQXKTNQ\8:EJ=E;Z;:0:Q9Q75OH]M"68QP(RD+OD9G=NI
M.!G  H Z/X _&_1/VC?@[X<\;>'YUFTKQ)9I=Q#()B8\/$V/XT<,A]U-<M^V
MG\6M;^"OPAT[6/#\T$%]<>)]$TR1I8A(I@NM1@MY5P>YCD8 ]B<]JW/@/^SK
MH_[.L?B*S\.RS6^A:YJTFKVVDA$2UT=Y57S8[=5 VQO(#)MZ!G;& <4O[2WP
M%@_:0^%[^&IM7O\ 076_L]3M[ZS2.26WGM;B.XB8+("C#?&N01R* .^X!QQF
MO%/VT/&/CSP7I/A>?PBNLV^ARZBZ>)=0T32H]5U33K7R7,;PVTF0ZF4*'*J[
M*O(4\X].^'?AG5?"?A:VLM9\077B?48BQEU&XMHK:2?))&4B"H,#C@#I7-_'
M#X'7_P 5+[1]3T3QIXC\$:[H9E%O=Z<8YH9HY  \<UM*K12CY5()7<I'!&2"
M )^S/X[A^)?P<TC5H?%]KXY64RQMK$%B+$W+)(RE9(/^64JD;74@893\J]**
MM_ 7X%:;\ / SZ-I]Y?ZC->7MQJNHZA>LK7.I7MPYDGGDV@*"[G.%     XH
$H __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
